Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Abstract Background Anti–vascular endothelial growth factor (anti-VEGF) agents have become the standard of care in neovascular age-related macular degeneration (nAMD). Despite generally excellent response rates to anti-VEGF therapy, some patients do not respond or may respond suboptimally. In the ca...
Main Authors: | Sam Razavi, Laurent Kodjikian, Audrey Giocanti-Aurégan, Ingrid Dufour, Eric Souied |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-02-01
|
Series: | BMC Ophthalmology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12886-021-01841-6 |
Similar Items
-
Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab
by: Rachel Hui Fen Lim, et al.
Published: (2017-03-01) -
Intravitreal Aflibercept Treatment Strategies in Routine Clinical Practice of Neovascular Age-Related Macular Degeneration in Belgium: A Retrospective Observational Study
by: Joke Ruys, et al.
Published: (2020-09-01) -
CFH Y402H polymorphism and response to intravitreal Ranibizumab in brazilian patients with neovascular age-related macular degeneration
by: Carlos Eduardo Veloso, et al. -
Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab
by: Nudleman E, et al.
Published: (2016-06-01) -
Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
by: Fouda SM, et al.
Published: (2017-03-01)